Views
4 years ago

C7 - AM Cafferata - 3/2017

  • Text
  • Clas
  • High
  • Ischemic
  • Flushing
  • Hdlc
  • I
  • Molecular
  • Lipolisis
  • Cafferata
  • Cardio
  • Libro
  • Grupo
  • Estudios
  • Niacin
  • Pacientes
  • Efectos
  • Incremento
  • Efecto
  • Niveles
  • Tratamiento
Uso racional del ácido nicotínico o niacina

EM Ylarri //

EM Ylarri // Farmacología cardiovascular. De la molécula al paciente. Dislipemias y aterogénesis ARBITER 6 HALTS Características: evaluación en individuos con enfermedad coronaria, LDLc

AM Cafferata // Uso racional del ácido nicotínico o niacina Scand1988;223:405-414. • Capuzzi DM, Baksh RI. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91: 1432-143. • Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta1999;1440:1-31. • Ganji SH, Zhang L-H, Kamanna VS, Kashyap ML. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol 2006;1:549-557. • Ganji SH, Qin S, Liu Y, et al. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells [abstract]. Artrioscler Thromb Vasc Biol 2004;24:E-125. • Ginsberg HN. Synthesis and secretion of apolipoprotein B from cultured liver cells. Curr Opin Lipidol 1995;6:275-280. • Grundy SM, Mok HYI, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24-36. • Morgan JM, SH, Tavintharan S, Zhu D, et al. Niacin non-competitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-1845. • Ganji SH, Qin S, Liu Y, et al. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells [abstract]. Artrioscler Thromb Vasc Biol 2004;24:E-125. • HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 highrisk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-1291. • Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler hromb Vasc Biol1997;17:2020-2028. • MolBenyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epiderma Langerhans cells. MolPharmacol 2006;70:1844-1849. • Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am CollCardiol. 2013;61(4):440-446 • Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol2006;126:2637-264. • Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659-665. • Morgan JM, Capuzzi DM, Baksh RI. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91: 1432-1436. • Nabokina SM, Kashyap ML, Said HM. Mechanism and regulation of human intestinal niacin uptake. Am J Physiol Cell Physiol 2005;289: C97-C103. • Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normo-cholesterolemic rabbits. Circulation 2005;111:1543–50. • Phan BA, Munoz L, Shadzi P, et al. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (stenosis progression, and clinical events in subjects with normal baseline glucose levels < 100mg/dl a combined analysis of the familial atherosclerosis treatment study (FATS), HDL-atherosclerosis treatment study (HATS), armed forces regression study (AFREGS), and carotid plaque composition by MRI during lipid-lowering (CPC) study. Am J Cardiol 2013;111(3):352-355. • Said HM, Nabokina SM, Balamurgan K, et al. Mechanism of nicotinic acid transport in human liver cells: EDITORIAL SCIENS 87

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015